These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

732 related items for PubMed ID: 33914595

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators.
    N Engl J Med; 2019 Jul 04; 381(1):13-24. PubMed ID: 31150574
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
    Hoy SM.
    Drugs; 2020 Oct 04; 80(15):1579-1585. PubMed ID: 32930958
    [Abstract] [Full Text] [Related]

  • 8. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
    Small EJ, Chi KN, Chowdhury S, Bevans KB, Bhaumik A, Saad F, Chung BH, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle SD, Uemura H, Smith MR, Agarwal N.
    Eur Urol Oncol; 2024 Aug 04; 7(4):844-852. PubMed ID: 38072759
    [Abstract] [Full Text] [Related]

  • 9. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Uemura H, Arai G, Uemura H, Suzuki H, Iijima K, Nishimura K, Fujii K, Hatayama T, Aoyama J, Deprince K, Lopez-Gitlitz A, McCarthy S, Larsen JS, Li J, Chi KN.
    Int J Urol; 2021 Mar 04; 28(3):280-287. PubMed ID: 33295007
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
    Chung BH, Huang J, Uemura H, Choi YD, Ye ZQ, Suzuki H, Kang TW, He DL, Joung JY, Brookman-May SD, McCarthy S, Bhaumik A, Singh A, Mundle S, Chowdhury S, Agarwal N, Ye DW, Chi KN, Uemura H.
    Asian J Androl; 2023 Nov 01; 25(6):653-661. PubMed ID: 37322621
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
    Uemura H, Arai G, Uemura H, Suzuki H, Aoyama J, Hatayama T, Ito M, Lefresne F, McCarthy S, Mundle S, He J, Chi KN.
    Int J Urol; 2022 Jun 01; 29(6):533-540. PubMed ID: 35293030
    [Abstract] [Full Text] [Related]

  • 13. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN.
    Br J Cancer; 2024 Jan 01; 130(1):73-81. PubMed ID: 37951974
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
    Dror CM, Chi KN.
    Future Oncol; 2020 Dec 01; 16(35):2905-2916. PubMed ID: 32885994
    [Abstract] [Full Text] [Related]

  • 16. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators.
    N Engl J Med; 2018 Apr 12; 378(15):1408-1418. PubMed ID: 29420164
    [Abstract] [Full Text] [Related]

  • 17. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 12; 37(1):501-511. PubMed ID: 31813086
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN.
    Lancet Oncol; 2019 May 12; 20(5):686-700. PubMed ID: 30987939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.